Alpha One Capital's Dan Niles likes JPMorgan, Oracle, Magna Intl, Gan Ltd in '21 ,,,,<---- GAN IS GUMMYBEAR ADVISORS TOP '21 PICK AS WELL!!!!!
Pitney Bowes raises 2021 e-commerce services pricing Dec. 02, 2020 9:22 AM ETPitney Bowes Inc. (PBI)By: Khyathi Dalal,SA News Editor7 Comments Pitney Bowes(NYSE:PBI)announceda 5.9% general rate increase (GRI) for ecommerce delivery services and a 4.9% increase for returns services, effective Jan.3, 2021. The 4.9% GRI applies to standard domestic returns services through the Pitney Bowes U.S. domestic network. "At a time when other carriers are passing most of their rate increases through various complicated surcharges, we're putting our customers in a position to easily anticipate and plan for their ecommerce logistics spend," Chief Revenue Officer, Global Ecommerce, Patrick Allard commented. Pitney Bowes announces pricing update amid continued surge in parcel volumes Ok that first blurb about pricing was Dec 2 then a little something today as well... an update and the blast off! I smell more trade here... Price hikes were higher than expected I would guess... ok folks I think we stumbled onto something... Returns are going to be huge PBI apparently participates in this somehow... Pitney Bowes launches same-day delivery 12/01 PBI Pitney Bowes announced the launch of Pitney Bowes same-day delivery through its cloud-based SendPro Online sending platform. Setting a new industry standard, Pitney Bowes said its same-day delivery raises the bar for cost-effective expedited services by providing access to a curated network of Pitney Bowes service providers, through a single shipping platform. Also launching is SendPro Delivery Assurance, a domestic delivery service for USPS Priority Mail business customers which, in the event of a shipment being delayed, enables the sender to request a credit for a shipping label charge.
PBI $ 6.41 Long ski slope gradual decline... $7.26 low side Target $9.16 Target! PBI will be our stock tomorrow....>>>>
Stoney lol, this Penumbra short... was all over the news 3 weeks ago fwiw. Every PM in the world went after this guy. Noooo. You never read what I write. I told you yesterday, that was a pure one day only call. And it worked out perfectly. Over $0.80/share. You know I know SNAP. See that's the thing I said last night Stoney.... we are in a market where everything is going up everyday. Anybody can come on here and throw a stock out to go long on. In this climate... that proves nothing about one's ability to play the game. There's a trillion kids all over Twitter that think they are trading gods. Here's what I say to that... If you want to call yourself a trading genius, then lets see you call out some shorts in a bull market and some longs in a bear. Then I'll be impressed. Aside from that.... pfff.... these kids are gonna lose it all the first time the market pulls back a decent amount and they say "holy moly, $XYZ was just at $80 last week.... its a steal at $62!!!!". They go all in with margin... and XYZ drops to $29. Game over. It hasn't happened yet, but it will. The drop last March didn't have this level of exuberant participation by this degree of newbies buying trash they have no clue about. Mother market is a mean bitch, and there's nothing new under the sun. Ever.
Nurse tests positive for COVID-19 week after getting Pfizer vaccine, KGTV says 06:56 PFE, BNTX A nurse in California tested positive for COVID-19 eight days after having received the vaccine developed by Pfizer (PFE) and partner BioNTech (BNTX), according to ABC News affiliate KGTV of San Diego. Dr. Christian Ramers, an infectious disease specialist with Family Health Centers of San Diego, points out that it is possible the nurse was infected before receiving the vaccine, adding "It's not unexpected at all. If you work through the numbers, this is exactly what we'd expect to happen if someone was exposed," according to KGTV's Michael Chen. ->If you want to call yourself a trading genius, then lets see you call out some shorts in a bull market and some longs in a bear.// I will give you a list of short candidates for a bull market if I can come up with one. AZN. Astra Zen may be a buy today. They have not had a Covid rally yet as they had a few setbacks which seem resolved. People are starting to realize how far behind we are on the vaccine rollout and when the stock market does the math I don't think it's going to like it. Maybe then I could come up with some longs in a bear market!
--Encore Wire price target raised to $70 from $59 at DA Davidson Not sure what these guys do. I like the price target hike! The common is a buck below their old PT and would seem in keeping with a real target modification. I dislike catch up price target raises when the analyst has a $20 PT on a $50 runaway train and then hikes his PT vastly from $20- $45! I throw those away. TJX price target raised to $78 from $70 at Guggenheim AlphaValue upgrades AstraZeneca, sees sentiment 'finally' improving 05:57 AZN AlphaValue analyst Amandeep Goyal upgraded AstraZeneca to Add from Reduce following the U.K.'s emergency use approval of the company's Covid-19 vaccine. The approval means "sentiment around Astra's share price should improve finally," Goyal tells investors in a research note. The analyst also increased AstraZeneca's premium on peer-based multiples to 40% from 35% to reflect prospective incremental cash flows from Alexion acquisition. Whitestone traffic outperforming shopping center peers, says JMP Securities WSR $7.82.....REIT**// A first for me! An " Itch Score! " Love it.... Evelo shares undervalued into atopic dermatitis data, says JMP Securities 05:49 EVLO JMP Securities analyst Gobind Singh reiterates an Outperform rating on Evelo Biosciences with a $27 price target and is bullish on EDP1815's opportunity in mild-to-moderate atopic dermatitis. The shares continue to remain undervalued heading into next month, when full results, including itchscore, among other patient-reported outcomes and biomarkers, will be presented, Singh tells investors in a research note. -->The $5.2B acquisition of Anacor by Pfizer (PFE) in 2016 was driven by expectations of over $2B peak sales with flagship asset Eucrisa in the same market, the analyst points out. However, Eucrisa's safety signal of burning/stinging sensation has limited its commercial success, notes Singh, who says EDP1815 does not have this safety signal. The analyst currently models $1.5B peak sales for EDP1815 in atopic dermatitis. Jesus this hits on all of stoney's pleasure points! $1.5 B peak sales market // a drug with a better safety profile than another...1 Month Time frame! not followed or talked about because " itching " isn't sexy. Hey I have skin issues Psorisis --I can't spell it but I have it and other stuff... This is interesting to me!!!
HEY VAN I GOT A NEW BUDDY BOSCO! HAVE YOU JOINED THE TEAM? I GAVE YOU AN INVITE YESTERDAY TO RIDE. RIDE WITH US-!